Institutional development · Industry collaboration · France
Strasbourg biotech AdipoPharma's diabetes molecule PATAS enters phase 1b clinical study
AdipoPharma, a Strasbourg biotech founded in 2017 and propelled by the technology transfer body Conectus, says its molecule PATAS is entering a phase 1b clinical study in people with type 2 diabetes.
Why it matters: Patients with type 2 diabetes are the population for the phase 1b clinical study that AdipoPharma's molecule PATAS is entering.
According to Réseau SATT, the network of French technology transfer acceleration companies, the molecule PATAS developed by Strasbourg biotech AdipoPharma is entering a phase 1b clinical study.
The network said the study concerns patients with type 2 diabetes.
Réseau SATT said AdipoPharma was created in 2017 and described the start-up as propelled by Conectus.
Réseau SATT called the step a major advance that illustrates how technology transfer carried by Conectus turns scientific discoveries into health innovations.
Editor’s view
Joseph Lopez, Collaboration Editor
AdipoPharma's molecule PATAS is entering a phase 1b clinical study in patients with type 2 diabetes, a step Réseau SATT presents as an example of technology transfer carried by Conectus.
